Reciprocal expression of the TNF family receptor herpes virus entry mediator and its ligand LIGHT on activated T cells: LIGHT down-regulates its own receptor

Y Morel, JM Schiano de Colella, J Harrop… - The Journal of …, 2000 - journals.aai.org
The TNF receptor (TNFR) family plays a central role in the development of the immune
response. Here we describe the reciprocal regulation of the recently identified TNFR superfamily …

Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma

…, R Lowsky, GL Shah, MA Perales, JMS De Colella… - Leukemia, 2021 - nature.com
Anti-PD-1 monoclonal antibodies yield high response rates in patients with relapsed/refractory
classic Hodgkin lymphoma (cHL), but most patients will eventually progress. Allogeneic …

Occurrence and severity of adverse events after autologous hematopoietic progenitor cell infusion are related to the amount of granulocytes in the apheresis product

…, A Charbonnier, D Coso, JM Schiano de Colella… - …, 2007 - Wiley Online Library
BACKGROUND: Adverse events (AEs) after hematopoietic progenitor cell (HPC) infusion are
rare but might be life‐threatening. These reactions have traditionally been associated with …

[HTML][HTML] Six-year results from RELEVANCE: lenalidomide plus rituximab (R2) versus rituximab-chemotherapy followed by rituximab maintenance in untreated …

…, L Nastoupil, P Feugier, JMS De Colella… - Journal of Clinical …, 2022 - ncbi.nlm.nih.gov
Immunochemotherapy has remained the frontline gold standard for patients with follicular
lymphoma (FL) needing systemic therapy 1-3; however, FL has been shown to be immune-…

Early 18F-FDG PET/CT response predicts survival in relapsed or refractory Hodgkin lymphoma treated with nivolumab

…, A Stamatoullas, JMS de Colella… - Journal of Nuclear …, 2020 - Soc Nuclear Med
Monoclonal antibodies (mAbs) against programmed cell death 1 (PD-1), such as nivolumab
and pembrolizumab, are associated with high response rates in patients with relapsed or …

Performance of CT Compared with 18F-FDG PET in Predicting the Efficacy of Nivolumab in Relapsed or Refractory Hodgkin Lymphoma

…, A Stamatoullas, JM Schiano de Colella… - Radiology, 2020 - pubs.rsna.org
Background CT and fluorine 18 ( 18 F) fluorodeoxyglucose (FDG) PET/CT performances
following immune therapy are not well known in patients with relapsed or refractory Hodgkin …

[HTML][HTML] Lenalidomide plus donor-lymphocytes infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high-risk multiple …

…, B Calmels, AM Stoppa, JMS De Colella… - Experimental …, 2012 - Elsevier
Myeloma relapse is the main cause of death after allogeneic stem cell transplantation. The
aim of our observational study was to evaluate the anti-myeloma effect of lenalidomide …

Unconventional immune-related phenomena observed using 18F-FDG PET/CT in Hodgkin lymphoma treated with anti PD-1 monoclonal antibodies

L Dercle, FZ Mokrane, JM Schiano de Colella… - European Journal of …, 2019 - Springer
The paradigm of response in Hodgkin lymphoma (HL) was developed in cytotoxic chemotherapies
and its use as a reference model for immune-modulatory regimens, which restores …

Long-Term Follow-Up of the Response-Adapted Intergroup EORTC/LYSA/FIL H10 Trial for Localized Hodgkin Lymphoma

…, L Specht, JM Schiano de Colella… - Journal of Clinical …, 2024 - ingentaconnect.com
Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned co-…

[HTML][HTML] Allogeneic stem cell transplantation in poor prognosis peripheral T-cell lymphoma: the impact of different donor type on outcome

…, JM Schiano de Colella, C Montes de Oca… - Bone Marrow …, 2021 - nature.com
We report the outcome of 68 patients with advanced peripheral T-cell lymphoma receiving
transplantation from haploidentical or from conventional donors. The 4-year OS, PFS, 2-year …